Literature DB >> 9559827

Susceptibilities of clinical and laboratory isolates of Blastomyces dermatitidis to ketoconazole, itraconazole, and fluconazole.

S W Chapman1, P D Rogers, M G Rinaldi, D C Sullivan.   

Abstract

Eighteen isolates of Blastomyces dermatitidis were evaluated for their in vitro susceptibilities to ketoconazole, itraconazole, and fluconazole. The MIC ranges were 0.1 to 0.4 microg/ml for ketoconazole, < or =0.018 to 0.07 microg/ml for itraconazole, and 2.5 to 4.0 microg/ml for fluconazole. The ranges for the minimal lethal concentrations were 0.2 to 0.8 microg/ml for ketoconazole, < or =0.018 to 0.07 microg/ml for itraconazole, and 10 to 40 microg/ml for fluconazole. Itraconazole was the most active agent against B. dermatitidis in vitro, while fluconazole was the least active. These results correlate with the clinical efficacies noted to date with doses of these agents used to treat blastomycosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559827      PMCID: PMC105586          DOI: 10.1128/AAC.42.4.978

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  P G Pappas; R W Bradsher; C A Kauffman; G A Cloud; C J Thomas; G D Campbell; S W Chapman; C Newman; W E Dismukes
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

2.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; M Bartlett; R Bowden; N X Chin; C Cooper; A Fothergill; M R McGinnis; P Menezes; S A Messer; P W Nelson; F C Odds; L Pasarell; J Peter; M A Pfaller; J H Rex; M G Rinaldi; G S Shankland; T J Walsh; I Weitzman
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

3.  High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.

Authors:  F Menichetti; M Fiorio; A Tosti; G Gatti; M Bruna Pasticci; F Miletich; M Marroni; D Bassetti; S Pauluzzi
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

Review 4.  Histoplasmosis and blastomycosis.

Authors:  R W Bradsher
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

Review 5.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

6.  Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole.

Authors:  A Ganer; E Arathoon; D A Stevens
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

7.  Pharmacology and toxicity of high-dose ketoconazole.

Authors:  A M Sugar; S G Alsip; J N Galgiani; J R Graybill; W E Dismukes; G A Cloud; P C Craven; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

8.  Treatment of coccidioidal meningitis with fluconazole.

Authors:  R M Tucker; J N Galgiani; D W Denning; L H Hanson; J R Graybill; K Sharkey; M R Eckman; C Salemi; R Libke; R A Klein
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

9.  Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories.

Authors:  A Espinel-Ingroff; L Steele-Moore; J N Galgiani
Journal:  Diagn Microbiol Infect Dis       Date:  1994-10       Impact factor: 2.803

10.  Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  P G Pappas; R W Bradsher; S W Chapman; C A Kauffman; A Dine; G A Cloud; W E Dismukes
Journal:  Clin Infect Dis       Date:  1995-02       Impact factor: 9.079

View more
  6 in total

1.  Antifungal therapeutics for dimorphic fungal pathogens.

Authors:  Kristie D Goughenour; Chad A Rappleye
Journal:  Virulence       Date:  2016-09-19       Impact factor: 5.882

2.  Antifungal Susceptibility of Emerging Dimorphic Pathogens in the Family Ajellomycetaceae.

Authors:  Karolina Dukik; Abdullah M S Al-Hatmi; Ilse Curfs-Breuker; Dirk Faro; Sybren de Hoog; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  In Vitro Antifungal Susceptibility of Yeast and Mold Phases of Isolates of Dimorphic Fungal Pathogen Emergomyces africanus (Formerly Emmonsia sp.) from HIV-Infected South African Patients.

Authors:  Tsidiso G Maphanga; Erika Britz; Thokozile G Zulu; Ruth S Mpembe; Serisha D Naicker; Ilan S Schwartz; Nelesh P Govender
Journal:  J Clin Microbiol       Date:  2017-03-29       Impact factor: 5.948

4.  Blastomycotic osteomyelitis associated with severe lameness in a horse.

Authors:  José L Méndez-Angulo; Megan E Swaab; Erin Malone; Erik J Olson; Mark D Chalkley; Betsy Aird; Christie Ward
Journal:  Can Vet J       Date:  2011-12       Impact factor: 1.008

5.  Human Blastomycosis in South Africa Caused by Blastomyces percursus and Blastomyces emzantsi sp. nov., 1967 to 2014.

Authors:  Tsidiso G Maphanga; Monica Birkhead; José F Muñoz; Mushal Allam; Thokozile G Zulu; Christina A Cuomo; Ilan S Schwartz; Arshad Ismail; Serisha D Naicker; Ruth S Mpembe; Craig Corcoran; Sybren de Hoog; Chris Kenyon; Andrew M Borman; John A Frean; Nelesh P Govender
Journal:  J Clin Microbiol       Date:  2020-02-24       Impact factor: 5.948

6.  Fungal Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.